Refractory Ventricular Tachycardia
Conditions
Brief summary
The investigators will compare the effects of PSGB(percutaneous stellate ganglion block) in patients with recurrent sustained VT/VF in spite of appropriate medical therapy and cardio-version/ defibrillation after correction of underlying correctable factors with those without PSGB by prospective randomized trail. PSGB will be performed every 3 days by anesthesiology specialist after cardiologist's request, until the stabilization of VT/VF. We will compare the frequency and episode number of VT/VF, procedure related complication, acute and long-term mortality.
Detailed description
Recurrent ventricular tachycardia(VT)/ fibrillation(VF) increases mortality, especially in patients with structural heart disease. It has been reported that cardiac sympathectomy reduces VT/VF episodes in patients with complex VT, long QT syndrome, catecholaminergic polymorphic VT, or myocarditis. However, cardiac sympathectomy operation is hard to conduct in patients with hemodynamically unstable recurrent VT/VF or electrical storm. Therefore, we hypothesized that bed-side percutaneous stellate ganglion block (PSGB) reduces VT/VF episodes and mortality in patients with repetitive VT/VF who are properly managed with optimal medical therapies.
Interventions
Antiarrhythmic drug
percutaneous stellate ganglion block (PSGB)
Sponsors
Yonsei University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
20 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
* Patients agreement of consent * AF patient age 20-85 * Patient are diagnosed Refractory Ventricular tachycardia * Patients who have generated Refractory Ventricular tachycardia despite of defibrillation and drug therapy * Patients with ICD have generated ICD shock or anti-tachycardia pacing despite of defibrillation and drug therapy
Exclusion criteria
* Patients who do not agree with study inclusion * Patients who do not taken stellate ganglion block due to unstable hemodynamic status * Patients have experienced major hemorrhagic complication * Patients of the DNR status * Patients with malignancy tumor, major neurogenic disease or gastrointestinal disease
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of VT/VF episodes after randomization | 5 days after randomization |
| Duration of VT/VF episodes after randomization | 5 days after randomization |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| mortality | 1 month after the enrollment | death, cause of death, |
| procedure related complication | 1 month after the enrollment | — |
Countries
South Korea
Contacts
Primary ContactHui-Nam Park, MD, Ph.D
Outcome results
None listed